MARKET

MNKD

MNKD

MannKind
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.220
-0.020
-1.61%
Closed 16:00 11/12 EST
OPEN
1.200
PREV CLOSE
1.240
HIGH
1.245
LOW
1.200
VOLUME
2.17M
TURNOVER
--
52 WEEK HIGH
2.340
52 WEEK LOW
0.9400
MARKET CAP
251.82M
P/E (TTM)
-3.3609
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MNKD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MNKD News

  • Introducing MannKind (NASDAQ:MNKD), The Stock That Collapsed 96%
  • Simply Wall St..10h ago
  • Assessing MannKind's Q3 - What Investors Need To Know
  • Seeking Alpha - Article.2d ago
  • MannKind Corporation (MNKD) CEO Michael Castagna on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.6d ago
  • MannKind Q3 Afrezza sales $6.4M; shares ahead 1% premarket
  • seekingalpha.6d ago

More

Industry

Biotechnology & Medical Research
+0.45%
Pharmaceuticals & Medical Research
+0.31%

Hot Stocks

Name
Price
%Change

About MNKD

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
More

Webull offers MannKind Corporation (MNKD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.